Found 14 hits for monomerid = 451801 Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kcal/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
Activin receptor type-1 [172-499]
(Homo sapiens (Human)) | BDBM451801
(US10710980, Example 33 | US10947218, Example 33)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(C2)C1CCOCC1 |r,wU:25.27,10.10,wD:23.25,13.14,(-3.92,5.73,;-2.58,4.96,;-1.25,5.73,;.08,4.96,;.08,3.42,;-1.25,2.65,;-2.58,3.42,;-3.92,2.65,;-5.25,3.42,;-3.92,1.11,;-5.41,.71,;-5.8,-.77,;-7.29,-1.17,;-8.38,-.08,;-9.87,-.48,;-7.98,1.4,;-6.5,1.8,;1.42,2.65,;1.42,1.11,;2.75,.34,;4.08,1.11,;4.08,2.65,;2.75,3.42,;5.42,.34,;5.58,1.87,;6.82,.97,;7.85,-.18,;7.08,-1.51,;5.58,-1.19,;7.71,-2.92,;6.81,-4.16,;7.43,-5.57,;8.96,-5.73,;9.87,-4.49,;9.24,-3.08,)| Show InChI InChI=1S/C28H36N4O3/c29-26-25(27(34)31-22-5-7-24(33)8-6-22)13-19(15-30-26)18-1-3-20(4-2-18)28-14-21(28)16-32(17-28)23-9-11-35-12-10-23/h1-4,13,15,21-24,33H,5-12,14,16-17H2,(H2,29,30)(H,31,34)/t21-,22-,24-,28+/m0/s1 | PDB
UniProtKB/SwissProt
GoogleScholar
AffyNet 
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 10 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 6 ul. Dose-response curves were generated by ... |
US Patent US10710980 (2020)
|
More data for this
Ligand-Target Pair | |
Bone morphogenetic protein receptor type-1A [198-525]
(Homo sapiens (Human)) | BDBM451801
(US10710980, Example 33 | US10947218, Example 33)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(C2)C1CCOCC1 |r,wU:25.27,10.10,wD:23.25,13.14,(-3.92,5.73,;-2.58,4.96,;-1.25,5.73,;.08,4.96,;.08,3.42,;-1.25,2.65,;-2.58,3.42,;-3.92,2.65,;-5.25,3.42,;-3.92,1.11,;-5.41,.71,;-5.8,-.77,;-7.29,-1.17,;-8.38,-.08,;-9.87,-.48,;-7.98,1.4,;-6.5,1.8,;1.42,2.65,;1.42,1.11,;2.75,.34,;4.08,1.11,;4.08,2.65,;2.75,3.42,;5.42,.34,;5.58,1.87,;6.82,.97,;7.85,-.18,;7.08,-1.51,;5.58,-1.19,;7.71,-2.92,;6.81,-4.16,;7.43,-5.57,;8.96,-5.73,;9.87,-4.49,;9.24,-3.08,)| Show InChI InChI=1S/C28H36N4O3/c29-26-25(27(34)31-22-5-7-24(33)8-6-22)13-19(15-30-26)18-1-3-20(4-2-18)28-14-21(28)16-32(17-28)23-9-11-35-12-10-23/h1-4,13,15,21-24,33H,5-12,14,16-17H2,(H2,29,30)(H,31,34)/t21-,22-,24-,28+/m0/s1 | UniProtKB/SwissProt
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 2.40E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 6 ul. Dose-response curves were generated by ... |
US Patent US10710980 (2020)
|
More data for this
Ligand-Target Pair | |
Activin receptor type-1 [172-499]
(Homo sapiens (Human)) | BDBM451801
(US10710980, Example 33 | US10947218, Example 33)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(C2)C1CCOCC1 |r,wU:25.27,10.10,wD:23.25,13.14,(-3.92,5.73,;-2.58,4.96,;-1.25,5.73,;.08,4.96,;.08,3.42,;-1.25,2.65,;-2.58,3.42,;-3.92,2.65,;-5.25,3.42,;-3.92,1.11,;-5.41,.71,;-5.8,-.77,;-7.29,-1.17,;-8.38,-.08,;-9.87,-.48,;-7.98,1.4,;-6.5,1.8,;1.42,2.65,;1.42,1.11,;2.75,.34,;4.08,1.11,;4.08,2.65,;2.75,3.42,;5.42,.34,;5.58,1.87,;6.82,.97,;7.85,-.18,;7.08,-1.51,;5.58,-1.19,;7.71,-2.92,;6.81,-4.16,;7.43,-5.57,;8.96,-5.73,;9.87,-4.49,;9.24,-3.08,)| Show InChI InChI=1S/C28H36N4O3/c29-26-25(27(34)31-22-5-7-24(33)8-6-22)13-19(15-30-26)18-1-3-20(4-2-18)28-14-21(28)16-32(17-28)23-9-11-35-12-10-23/h1-4,13,15,21-24,33H,5-12,14,16-17H2,(H2,29,30)(H,31,34)/t21-,22-,24-,28+/m0/s1 | PDB
UniProtKB/SwissProt
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 20 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1... |
US Patent US10710980 (2020)
|
More data for this
Ligand-Target Pair | |
Activin receptor type-1 [172-499,R206H]
(Homo sapiens (Human)) | BDBM451801
(US10710980, Example 33 | US10947218, Example 33)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(C2)C1CCOCC1 |r,wU:25.27,10.10,wD:23.25,13.14,(-3.92,5.73,;-2.58,4.96,;-1.25,5.73,;.08,4.96,;.08,3.42,;-1.25,2.65,;-2.58,3.42,;-3.92,2.65,;-5.25,3.42,;-3.92,1.11,;-5.41,.71,;-5.8,-.77,;-7.29,-1.17,;-8.38,-.08,;-9.87,-.48,;-7.98,1.4,;-6.5,1.8,;1.42,2.65,;1.42,1.11,;2.75,.34,;4.08,1.11,;4.08,2.65,;2.75,3.42,;5.42,.34,;5.58,1.87,;6.82,.97,;7.85,-.18,;7.08,-1.51,;5.58,-1.19,;7.71,-2.92,;6.81,-4.16,;7.43,-5.57,;8.96,-5.73,;9.87,-4.49,;9.24,-3.08,)| Show InChI InChI=1S/C28H36N4O3/c29-26-25(27(34)31-22-5-7-24(33)8-6-22)13-19(15-30-26)18-1-3-20(4-2-18)28-14-21(28)16-32(17-28)23-9-11-35-12-10-23/h1-4,13,15,21-24,33H,5-12,14,16-17H2,(H2,29,30)(H,31,34)/t21-,22-,24-,28+/m0/s1 | PDB
UniProtKB/SwissProt
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 14 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1... |
US Patent US10710980 (2020)
|
More data for this
Ligand-Target Pair | |
Serine/threonine-protein kinase receptor R3 [166-493]
(Homo sapiens (Human)) | BDBM451801
(US10710980, Example 33 | US10947218, Example 33)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(C2)C1CCOCC1 |r,wU:25.27,10.10,wD:23.25,13.14,(-3.92,5.73,;-2.58,4.96,;-1.25,5.73,;.08,4.96,;.08,3.42,;-1.25,2.65,;-2.58,3.42,;-3.92,2.65,;-5.25,3.42,;-3.92,1.11,;-5.41,.71,;-5.8,-.77,;-7.29,-1.17,;-8.38,-.08,;-9.87,-.48,;-7.98,1.4,;-6.5,1.8,;1.42,2.65,;1.42,1.11,;2.75,.34,;4.08,1.11,;4.08,2.65,;2.75,3.42,;5.42,.34,;5.58,1.87,;6.82,.97,;7.85,-.18,;7.08,-1.51,;5.58,-1.19,;7.71,-2.92,;6.81,-4.16,;7.43,-5.57,;8.96,-5.73,;9.87,-4.49,;9.24,-3.08,)| Show InChI InChI=1S/C28H36N4O3/c29-26-25(27(34)31-22-5-7-24(33)8-6-22)13-19(15-30-26)18-1-3-20(4-2-18)28-14-21(28)16-32(17-28)23-9-11-35-12-10-23/h1-4,13,15,21-24,33H,5-12,14,16-17H2,(H2,29,30)(H,31,34)/t21-,22-,24-,28+/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 220 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1... |
US Patent US10710980 (2020)
|
More data for this
Ligand-Target Pair | |
TGF-beta receptor type-1 [162-503]
(Homo sapiens (Human)) | BDBM451801
(US10710980, Example 33 | US10947218, Example 33)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(C2)C1CCOCC1 |r,wU:25.27,10.10,wD:23.25,13.14,(-3.92,5.73,;-2.58,4.96,;-1.25,5.73,;.08,4.96,;.08,3.42,;-1.25,2.65,;-2.58,3.42,;-3.92,2.65,;-5.25,3.42,;-3.92,1.11,;-5.41,.71,;-5.8,-.77,;-7.29,-1.17,;-8.38,-.08,;-9.87,-.48,;-7.98,1.4,;-6.5,1.8,;1.42,2.65,;1.42,1.11,;2.75,.34,;4.08,1.11,;4.08,2.65,;2.75,3.42,;5.42,.34,;5.58,1.87,;6.82,.97,;7.85,-.18,;7.08,-1.51,;5.58,-1.19,;7.71,-2.92,;6.81,-4.16,;7.43,-5.57,;8.96,-5.73,;9.87,-4.49,;9.24,-3.08,)| Show InChI InChI=1S/C28H36N4O3/c29-26-25(27(34)31-22-5-7-24(33)8-6-22)13-19(15-30-26)18-1-3-20(4-2-18)28-14-21(28)16-32(17-28)23-9-11-35-12-10-23/h1-4,13,15,21-24,33H,5-12,14,16-17H2,(H2,29,30)(H,31,34)/t21-,22-,24-,28+/m0/s1 | PDB
UniProtKB/SwissProt
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 1.80E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1... |
US Patent US10710980 (2020)
|
More data for this
Ligand-Target Pair | |
Bone morphogenetic protein receptor type-1B
(Homo sapiens (Human)) | BDBM451801
(US10710980, Example 33 | US10947218, Example 33)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(C2)C1CCOCC1 |r,wU:25.27,10.10,wD:23.25,13.14,(-3.92,5.73,;-2.58,4.96,;-1.25,5.73,;.08,4.96,;.08,3.42,;-1.25,2.65,;-2.58,3.42,;-3.92,2.65,;-5.25,3.42,;-3.92,1.11,;-5.41,.71,;-5.8,-.77,;-7.29,-1.17,;-8.38,-.08,;-9.87,-.48,;-7.98,1.4,;-6.5,1.8,;1.42,2.65,;1.42,1.11,;2.75,.34,;4.08,1.11,;4.08,2.65,;2.75,3.42,;5.42,.34,;5.58,1.87,;6.82,.97,;7.85,-.18,;7.08,-1.51,;5.58,-1.19,;7.71,-2.92,;6.81,-4.16,;7.43,-5.57,;8.96,-5.73,;9.87,-4.49,;9.24,-3.08,)| Show InChI InChI=1S/C28H36N4O3/c29-26-25(27(34)31-22-5-7-24(33)8-6-22)13-19(15-30-26)18-1-3-20(4-2-18)28-14-21(28)16-32(17-28)23-9-11-35-12-10-23/h1-4,13,15,21-24,33H,5-12,14,16-17H2,(H2,29,30)(H,31,34)/t21-,22-,24-,28+/m0/s1 | PDB
UniProtKB/SwissProt
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 2.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
NOVARTIS AG
US Patent
| Assay Description
A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20... |
US Patent US10947218 (2021)
|
More data for this
Ligand-Target Pair | |
Activin receptor type-1 [172-499]
(Homo sapiens (Human)) | BDBM451801
(US10710980, Example 33 | US10947218, Example 33)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(C2)C1CCOCC1 |r,wU:25.27,10.10,wD:23.25,13.14,(-3.92,5.73,;-2.58,4.96,;-1.25,5.73,;.08,4.96,;.08,3.42,;-1.25,2.65,;-2.58,3.42,;-3.92,2.65,;-5.25,3.42,;-3.92,1.11,;-5.41,.71,;-5.8,-.77,;-7.29,-1.17,;-8.38,-.08,;-9.87,-.48,;-7.98,1.4,;-6.5,1.8,;1.42,2.65,;1.42,1.11,;2.75,.34,;4.08,1.11,;4.08,2.65,;2.75,3.42,;5.42,.34,;5.58,1.87,;6.82,.97,;7.85,-.18,;7.08,-1.51,;5.58,-1.19,;7.71,-2.92,;6.81,-4.16,;7.43,-5.57,;8.96,-5.73,;9.87,-4.49,;9.24,-3.08,)| Show InChI InChI=1S/C28H36N4O3/c29-26-25(27(34)31-22-5-7-24(33)8-6-22)13-19(15-30-26)18-1-3-20(4-2-18)28-14-21(28)16-32(17-28)23-9-11-35-12-10-23/h1-4,13,15,21-24,33H,5-12,14,16-17H2,(H2,29,30)(H,31,34)/t21-,22-,24-,28+/m0/s1 | PDB
UniProtKB/SwissProt
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 10 | n/a | n/a | n/a | n/a | n/a | n/a |
NOVARTIS AG
US Patent
| Assay Description
A kinase selectivity panel which measures autophosphorylation using the ADP-Glo Kinase Assay (Promega, V9101) was set-up for wild-type ALK2 (aa172-49... |
US Patent US10947218 (2021)
|
More data for this
Ligand-Target Pair | |
Bone morphogenetic protein receptor type-1A [198-525]
(Homo sapiens (Human)) | BDBM451801
(US10710980, Example 33 | US10947218, Example 33)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(C2)C1CCOCC1 |r,wU:25.27,10.10,wD:23.25,13.14,(-3.92,5.73,;-2.58,4.96,;-1.25,5.73,;.08,4.96,;.08,3.42,;-1.25,2.65,;-2.58,3.42,;-3.92,2.65,;-5.25,3.42,;-3.92,1.11,;-5.41,.71,;-5.8,-.77,;-7.29,-1.17,;-8.38,-.08,;-9.87,-.48,;-7.98,1.4,;-6.5,1.8,;1.42,2.65,;1.42,1.11,;2.75,.34,;4.08,1.11,;4.08,2.65,;2.75,3.42,;5.42,.34,;5.58,1.87,;6.82,.97,;7.85,-.18,;7.08,-1.51,;5.58,-1.19,;7.71,-2.92,;6.81,-4.16,;7.43,-5.57,;8.96,-5.73,;9.87,-4.49,;9.24,-3.08,)| Show InChI InChI=1S/C28H36N4O3/c29-26-25(27(34)31-22-5-7-24(33)8-6-22)13-19(15-30-26)18-1-3-20(4-2-18)28-14-21(28)16-32(17-28)23-9-11-35-12-10-23/h1-4,13,15,21-24,33H,5-12,14,16-17H2,(H2,29,30)(H,31,34)/t21-,22-,24-,28+/m0/s1 | UniProtKB/SwissProt
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 2.40E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
NOVARTIS AG
US Patent
| Assay Description
A kinase selectivity panel which measures autophosphorylation using the ADP-Glo Kinase Assay (Promega, V9101) was set-up for wild-type ALK2 (aa172-49... |
US Patent US10947218 (2021)
|
More data for this
Ligand-Target Pair | |
Activin receptor type-1 [172-499]
(Homo sapiens (Human)) | BDBM451801
(US10710980, Example 33 | US10947218, Example 33)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(C2)C1CCOCC1 |r,wU:25.27,10.10,wD:23.25,13.14,(-3.92,5.73,;-2.58,4.96,;-1.25,5.73,;.08,4.96,;.08,3.42,;-1.25,2.65,;-2.58,3.42,;-3.92,2.65,;-5.25,3.42,;-3.92,1.11,;-5.41,.71,;-5.8,-.77,;-7.29,-1.17,;-8.38,-.08,;-9.87,-.48,;-7.98,1.4,;-6.5,1.8,;1.42,2.65,;1.42,1.11,;2.75,.34,;4.08,1.11,;4.08,2.65,;2.75,3.42,;5.42,.34,;5.58,1.87,;6.82,.97,;7.85,-.18,;7.08,-1.51,;5.58,-1.19,;7.71,-2.92,;6.81,-4.16,;7.43,-5.57,;8.96,-5.73,;9.87,-4.49,;9.24,-3.08,)| Show InChI InChI=1S/C28H36N4O3/c29-26-25(27(34)31-22-5-7-24(33)8-6-22)13-19(15-30-26)18-1-3-20(4-2-18)28-14-21(28)16-32(17-28)23-9-11-35-12-10-23/h1-4,13,15,21-24,33H,5-12,14,16-17H2,(H2,29,30)(H,31,34)/t21-,22-,24-,28+/m0/s1 | PDB
UniProtKB/SwissProt
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 20 | n/a | n/a | n/a | n/a | n/a | n/a |
NOVARTIS AG
US Patent
| Assay Description
A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20... |
US Patent US10947218 (2021)
|
More data for this
Ligand-Target Pair | |
Activin receptor type-1 [172-499,R206H]
(Homo sapiens (Human)) | BDBM451801
(US10710980, Example 33 | US10947218, Example 33)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(C2)C1CCOCC1 |r,wU:25.27,10.10,wD:23.25,13.14,(-3.92,5.73,;-2.58,4.96,;-1.25,5.73,;.08,4.96,;.08,3.42,;-1.25,2.65,;-2.58,3.42,;-3.92,2.65,;-5.25,3.42,;-3.92,1.11,;-5.41,.71,;-5.8,-.77,;-7.29,-1.17,;-8.38,-.08,;-9.87,-.48,;-7.98,1.4,;-6.5,1.8,;1.42,2.65,;1.42,1.11,;2.75,.34,;4.08,1.11,;4.08,2.65,;2.75,3.42,;5.42,.34,;5.58,1.87,;6.82,.97,;7.85,-.18,;7.08,-1.51,;5.58,-1.19,;7.71,-2.92,;6.81,-4.16,;7.43,-5.57,;8.96,-5.73,;9.87,-4.49,;9.24,-3.08,)| Show InChI InChI=1S/C28H36N4O3/c29-26-25(27(34)31-22-5-7-24(33)8-6-22)13-19(15-30-26)18-1-3-20(4-2-18)28-14-21(28)16-32(17-28)23-9-11-35-12-10-23/h1-4,13,15,21-24,33H,5-12,14,16-17H2,(H2,29,30)(H,31,34)/t21-,22-,24-,28+/m0/s1 | PDB
UniProtKB/SwissProt
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 14 | n/a | n/a | n/a | n/a | n/a | n/a |
NOVARTIS AG
US Patent
| Assay Description
A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20... |
US Patent US10947218 (2021)
|
More data for this
Ligand-Target Pair | |
Serine/threonine-protein kinase receptor R3 [166-493]
(Homo sapiens (Human)) | BDBM451801
(US10710980, Example 33 | US10947218, Example 33)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(C2)C1CCOCC1 |r,wU:25.27,10.10,wD:23.25,13.14,(-3.92,5.73,;-2.58,4.96,;-1.25,5.73,;.08,4.96,;.08,3.42,;-1.25,2.65,;-2.58,3.42,;-3.92,2.65,;-5.25,3.42,;-3.92,1.11,;-5.41,.71,;-5.8,-.77,;-7.29,-1.17,;-8.38,-.08,;-9.87,-.48,;-7.98,1.4,;-6.5,1.8,;1.42,2.65,;1.42,1.11,;2.75,.34,;4.08,1.11,;4.08,2.65,;2.75,3.42,;5.42,.34,;5.58,1.87,;6.82,.97,;7.85,-.18,;7.08,-1.51,;5.58,-1.19,;7.71,-2.92,;6.81,-4.16,;7.43,-5.57,;8.96,-5.73,;9.87,-4.49,;9.24,-3.08,)| Show InChI InChI=1S/C28H36N4O3/c29-26-25(27(34)31-22-5-7-24(33)8-6-22)13-19(15-30-26)18-1-3-20(4-2-18)28-14-21(28)16-32(17-28)23-9-11-35-12-10-23/h1-4,13,15,21-24,33H,5-12,14,16-17H2,(H2,29,30)(H,31,34)/t21-,22-,24-,28+/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 220 | n/a | n/a | n/a | n/a | n/a | n/a |
NOVARTIS AG
US Patent
| Assay Description
A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20... |
US Patent US10947218 (2021)
|
More data for this
Ligand-Target Pair | |
TGF-beta receptor type-1 [162-503]
(Homo sapiens (Human)) | BDBM451801
(US10710980, Example 33 | US10947218, Example 33)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(C2)C1CCOCC1 |r,wU:25.27,10.10,wD:23.25,13.14,(-3.92,5.73,;-2.58,4.96,;-1.25,5.73,;.08,4.96,;.08,3.42,;-1.25,2.65,;-2.58,3.42,;-3.92,2.65,;-5.25,3.42,;-3.92,1.11,;-5.41,.71,;-5.8,-.77,;-7.29,-1.17,;-8.38,-.08,;-9.87,-.48,;-7.98,1.4,;-6.5,1.8,;1.42,2.65,;1.42,1.11,;2.75,.34,;4.08,1.11,;4.08,2.65,;2.75,3.42,;5.42,.34,;5.58,1.87,;6.82,.97,;7.85,-.18,;7.08,-1.51,;5.58,-1.19,;7.71,-2.92,;6.81,-4.16,;7.43,-5.57,;8.96,-5.73,;9.87,-4.49,;9.24,-3.08,)| Show InChI InChI=1S/C28H36N4O3/c29-26-25(27(34)31-22-5-7-24(33)8-6-22)13-19(15-30-26)18-1-3-20(4-2-18)28-14-21(28)16-32(17-28)23-9-11-35-12-10-23/h1-4,13,15,21-24,33H,5-12,14,16-17H2,(H2,29,30)(H,31,34)/t21-,22-,24-,28+/m0/s1 | PDB
UniProtKB/SwissProt
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 1.80E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
NOVARTIS AG
US Patent
| Assay Description
A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20... |
US Patent US10947218 (2021)
|
More data for this
Ligand-Target Pair | |
Bone morphogenetic protein receptor type-1B
(Homo sapiens (Human)) | BDBM451801
(US10710980, Example 33 | US10947218, Example 33)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(C2)C1CCOCC1 |r,wU:25.27,10.10,wD:23.25,13.14,(-3.92,5.73,;-2.58,4.96,;-1.25,5.73,;.08,4.96,;.08,3.42,;-1.25,2.65,;-2.58,3.42,;-3.92,2.65,;-5.25,3.42,;-3.92,1.11,;-5.41,.71,;-5.8,-.77,;-7.29,-1.17,;-8.38,-.08,;-9.87,-.48,;-7.98,1.4,;-6.5,1.8,;1.42,2.65,;1.42,1.11,;2.75,.34,;4.08,1.11,;4.08,2.65,;2.75,3.42,;5.42,.34,;5.58,1.87,;6.82,.97,;7.85,-.18,;7.08,-1.51,;5.58,-1.19,;7.71,-2.92,;6.81,-4.16,;7.43,-5.57,;8.96,-5.73,;9.87,-4.49,;9.24,-3.08,)| Show InChI InChI=1S/C28H36N4O3/c29-26-25(27(34)31-22-5-7-24(33)8-6-22)13-19(15-30-26)18-1-3-20(4-2-18)28-14-21(28)16-32(17-28)23-9-11-35-12-10-23/h1-4,13,15,21-24,33H,5-12,14,16-17H2,(H2,29,30)(H,31,34)/t21-,22-,24-,28+/m0/s1 | PDB
UniProtKB/SwissProt
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 2.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1... |
US Patent US10710980 (2020)
|
More data for this
Ligand-Target Pair | |
Search and Browse
